Full Papers
Significance of HLA-B*51 allele expression in Crohn’s disease: a case-control study
A. Kostianovsky1, P.E. Llanquimán2, P.A. Olivera3, S.A. Muñoz4, I. Gandino5, A.O. Orden6, F. Dal Pra7, S. Teper8, M.C. Khoury9, A.M. Sambuelli10, A. Allievi11
- Internal Medicine Section, Department of Medicine, CEMIC University Hospital, Buenos Aires, Argentina.
- Inflammatory Bowel Disease Group, Hospital Dr. Carlos B. Udaondo, Buenos Aires, Argentina.
- Gastroenterology Section, Department of Medicine, CEMIC University Hospital, Buenos Aires, Argentina.
- Consultorio de Enfermedades Autoinmunes, Buenos Aires, Argentina.
- Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina.
- Clínica San Camilo, Buenos Aires, Argentina.
- Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina.
- Histocompatibility Laboratory, CEMIC University Hospital, Buenos Aires, Argentina.
- Hospital Dr. Carlos B. Udaondo, Buenos Aires, Argentina.
- Inflammatory Bowel Disease Group, Hospital Dr. Carlos B. Udaondo, Buenos Aires, Argentina.
- Consultorio de Enfermedades Autoinmunes, Buenos Aires, Argentina. beto.allievi@gmail.com
CER16395
2023 Vol.41, N°10
PI 2044, PF 2047
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 37140714 [PubMed]
Received: 24/11/2022
Accepted : 24/03/2023
In Press: 28/04/2023
Published: 30/10/2023
Abstract
OBJECTIVES:
Crohn’s disease (CD) and Behçet’s disease (BD) are two autoinflammatory diseases that share clinical and pathogenic features. Furthermore, when BD involves the gastrointestinal tract, it is extremely difficult to distinguish endoscopic lesions from CD lesions. HLA-B*51 allele expression is highly associated with BD diagnosis. In this study we analysed HLA-B*51 status in 70 Argentine patients with confirmed CD diagnosis and compared it to our previous Argentine BD cohort, with the aim of finding similarities or differences between these two diseases regarding HLA-B*51 status.
METHODS:
This is a multi-centre case-control study, including 70 patients with confirmed CD diagnosis, who underwent HLA-B*51 allele status testing; the results were compared to our previous BD cohort of 34 patients.
RESULTS:
Among patients with CD, 12.85% were positive for the HLA-B*51 allele, compared with 38.24% patients with BD (OR=0.238; 95% CI=0.089-0.637; p=0.004).
CONCLUSIONS:
Our finding suggests that determination of HLA-B*51 allele status may contribute to the differential diagnosis between CD and BD.
